PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11556469

Study of normal values in coagulation profile.

K Pathepchotiwong·P Tantiniti·C Sutthithampanich
View original source ↗Export metadata ↓

Abstract

The objective of the present work was to study normal values of hemostasis parameters in healthy volunteers using Behring Coagulation Timer (BCT). Plasma was divided into 2 parts fresh plasma and lyophilized plasma. It was found that the mean +/- SD of prothrombin time (PT) and activated partial thromboplastin time (APTT) in fresh plasma (n = 37) were 11.95 + 0.7 and 40.52 +/- 5.30 seconds respectively. The means + SD of coagulation factors I, II, VII, VIII and IX were 2.55 +/- 0.73 g/l (n = 36), 82.28 +/- 10.28 per cent (n = 37), 82.79 +/- 19.36 per cent (n=32), 89.13 +/- 24.17 per cent (n = 37), 94.11 +/- 16.29 per cent (n=31) respectively. The normal ranges (p5-p95) of PT, APTT and coagulation factors I, II, VII, VIII and IX were 10.8-13.3 sec, 31.4-48.0 sec and 1.82-4.65 g/l, 64.83-96.5 per cent, 46.88-113.5 per cent, 52.44-127.61 per cent and 67.87-116.94 per cent respectively. Comparison of PT, APTT between fresh plasma and lyophilized plasma were statistically different (Wilcoxon match-pair signed rank test, p < 0.05), while F I, II, VIII and F.IX in fresh plasma were increased more significantly than lyophilized plasma.

Explore related subjects

Blood Coagulation TestsHumansReference ValuesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Pathepchotiwong, P Tantiniti, C Sutthithampanich. 2001. Study of normal values in coagulation profile.. https://pubmed.ncbi.nlm.nih.gov/11556469/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.

In some mild haemophilia A patients (discrepant haemophilia), factor VIII coagulant activity (FVIII:C) levels, by one-stage assay are more than double than those by two-stage assay. This may be due to the longer incubation times (10-12 min) in the two-stage assay. This study aimed to determine the time course of the activation phase of the two-stage assay, using both classical coagulation and chromogenic detection methods. In both systems, for equivalent patients (equivalent FVIII:C levels by one-stage and two-stage assays, n = 6, all different mutations), similar FVIII:C results were obtained with short- or long-incubation times. In contrast, plasma from discrepant patients (n = 8, five different mutations) showed higher FVIII:C at shorter incubation times than after longer incubation times. In the chromogenic assay, FVIII:C levels were higher after incubation for 2 min (23-56%, mean 41%) than after 10 min (19-41%, mean 29%). In the classical coagulation assay, FVIII:C levels were higher at shorter incubation times (21-64%, mean 37%) than with the longer incubation times usually used (13-29%, mean 23%). These time-course experiments have verified that the longer incubation time used in the two-stage assay is at least partly responsible for the lower FVIII:C measured by that assay in discrepant haemophilia.

Blood Coagulation Tests↗
PubMed2007

Von Willebrand disease within the collective of haemophilic patients as reason for unexpected bleeding episodes.

In the treatment of haemophilia A and B, recombinant coagulation factors are increasingly replacing plasma-derived factor VIII and IX concentrates. Although provided with replacement therapy, individual patients may exhibit bleeding episodes, which are difficult to control. These bleeds may be caused by von Willebrand disease (VWD) as an additional underlying coagulation disorder. We report in the present study our experience that in the collective of haemophilic patients, VWD must be anticipated at least with the same order of magnitude as it appears in a normal healthy population. Among the patients at our treatment centre, two patients (1.5%) were identified as suffering from VWD in addition to haemophilia A. In the collective of haemophilia B patients at our centre, three patients (10%) with VWD were found. Two of these patients exhibited unexpected severe bleeding episodes, which could only satisfactorily be controlled by the administration of Haemate-P or DDAVP supplementary to the recombinant coagulation factor concentrate.

Blood Coagulation Tests↗